Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS vs ATACAND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Treatment of hypertension (FDA-approved),Cardiovascular risk reduction in patients unable to take ACE inhibitors (off-label)
Treatment of hypertension,Treatment of heart failure (NYHA class II-IV and left ventricular systolic dysfunction) to reduce cardiovascular death and hospitalization for heart failure
40-80 mg orally once daily.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing. Steady-state achieved in 5-7 days.
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Telmisartan is metabolized by glucuronidation via UGT1A3 and UGT2B7; minimal CYP450 metabolism.
Candesartan is primarily metabolized by ester hydrolysis to its active metabolite, candesartan, and further undergoes O-deethylation by CYP2C9 (minor route).
Primarily biliary/fecal (approximately 60% as unchanged drug); renal elimination accounts for about 40% (mostly unchanged drug and inactive metabolites). Total recovery in feces: 60-70%; urine: 30-40%.
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Highly bound (>99.5%), primarily to albumin and α1-acid glycoprotein. Binding is saturable at high concentrations but clinically not significant at therapeutic doses.
High protein binding: >99%, primarily to serum albumin.
Apparent volume of distribution: approximately 500 L (about 7 L/kg), indicating extensive extravascular distribution.
Volume of distribution (Vd) is approximately 0.13 L/kg (mean 9 L). This low Vd indicates limited extravascular distribution, consistent with high plasma protein binding.
Oral bioavailability is variable, approximately 40-60% (mean 50%) due to first-pass metabolism. Food reduces bioavailability by about 20%, but clinical effect is not significantly altered.
Absolute oral bioavailability is approximately 15% (prodrug candesartan cilexetil is completely converted to active candesartan during absorption). Food does not affect bioavailability.
No dose adjustment required for GFR ≥30 m L/min. Not studied in GFR <30 m L/min or dialysis; use caution.
No initial dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min (including dialysis), initiate at 4 mg once daily and titrate cautiously with monitoring.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), maximum dose is 40 mg once daily.
For Child-Pugh Class A or B: initiate at 4 mg once daily and titrate cautiously. Child-Pugh Class C: not recommended (no data).
Safety and efficacy not established in pediatric patients (<18 years).
For children ≥1 year and <6 years: 0.2-0.4 mg/kg/day once daily or divided twice daily; maximum 0.6 mg/kg/day (up to 32 mg/day). For children ≥6 years: 4-8 mg once initially; may increase to 16 mg once daily (or 32 mg daily in larger children).
No specific dose adjustment needed; start at lower end of dosing range (40 mg) due to possible increased sensitivity.
Start at 4 mg once daily in patients ≥75 years; adjust based on blood pressure response and renal function (e.g., GFR <30 m L/min).
No FDA boxed warning.
When pregnancy is detected, discontinue ATACAND as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Fetal toxicity: Use in pregnancy can cause injury and death to the fetus; discontinue when pregnancy is detected.,Hypotension in volume- or salt-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant K+ supplements/sparing diuretics,Avoid coadministration with aliskiren in patients with diabetes
Hypotension: Symptomatic hypotension may occur in volume-depleted patients or those with heart failure.,Hyperkalemia: Monitor serum potassium, especially in patients with renal impairment or on potassium-sparing diuretics.,Renal impairment: Use caution in patients with renal artery stenosis or severe renal impairment; monitor renal function.,Fetal/neonatal morbidity and mortality: As noted in black box warning.,Avoid use in patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney.
Concomitant use with aliskiren in patients with diabetes mellitus,Known hypersensitivity to telmisartan or any component,Pregnancy (second and third trimesters)
Hypersensitivity to candesartan or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
No specific food restrictions. Avoid salt substitutes containing potassium chloride. Maintain consistent dietary habits to avoid fluctuations in blood pressure. Grapefruit juice has no known interaction but other drugs may be affected; consult pharmacist for all medications.
No significant food interactions. Avoid potassium-rich foods (e.g., bananas, oranges, spinach, avocados) in large amounts if also taking potassium supplements or potassium-sparing diuretics. Salt substitutes containing potassium chloride should be used cautiously.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester exposure does not appear to increase the risk of congenital anomalies, but should be avoided due to potential unknown risks. Oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and hyperkalemia are risks associated with second and third trimester exposure.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects, hypotension, anuria) due to direct renin-angiotensin system blockade. Risk of neonatal renal failure and hypotension if exposed after 20 weeks gestation.
No data on the excretion of telmisartan into human milk are available. Telmisartan is excreted in the milk of lactating rats. Because of the potential for adverse effects in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio is unknown.
No data on candesartan in human milk; animal studies detect drug in milk. M/P ratio unknown. Avoid breastfeeding due to potential risk of neonatal hypotension and renal impairment.
No dose adjustment guidelines are available due to lack of pharmacokinetic studies in pregnancy. However, due to the risks associated with RAS inhibition, telmisartan should be discontinued as soon as pregnancy is detected, and alternative antihypertensive therapy should be initiated if needed.
Avoid use in second and third trimesters due to fetotoxicity. If inadvertent exposure occurs, discontinue drug immediately. No dose adjustment recommended for first trimester use, but consider alternative antihypertensive agent throughout pregnancy.
Monitor renal function and serum potassium before and during therapy, especially in patients with renal impairment or on potassium-sparing diuretics. May cause a rise in serum creatinine; usually minor and reversible. Avoid use in patients with biliary obstructive disorders or severe hepatic impairment due to primarily biliary excretion. Can be used with or without food; consistency recommended to avoid variability in absorption. Combination with aliskiren is contraindicated in diabetes. Adjust dose in patients with hepatic impairment; initial dose 40 mg once daily.
ATACAND (candesartan cilexetil) is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation or dose adjustment. Avoid use in pregnancy (Category D). May cause angioedema; discontinue immediately if occurs. Dual blockade with ACE inhibitors or aliskiren increases risk of hypotension, hyperkalemia, and renal impairment.
Take this medication exactly as prescribed, usually once daily, with or without food. Try to take it at the same time each day.,Do not stop taking this medicine without consulting your doctor, even if you feel well. High blood pressure often has no symptoms.,If you have a pregnancy potential, use effective contraception and notify your doctor immediately if you become pregnant. This drug can harm an unborn baby.,Avoid alcohol and use caution when driving or operating machinery until you know how this medicine affects you, as dizziness may occur.,Do not use salt substitutes containing potassium without your doctor's approval. This medication may increase your potassium levels.,Stay adequately hydrated, especially during exercise or in hot weather, to prevent low blood pressure. Dehydration may increase the risk of low blood pressure.,Report any signs of infection (fever, sore throat) or swelling of the face, lips, or tongue, which may indicate a serious allergic reaction.,Keep all appointments for blood pressure checks and lab work (kidney function and potassium levels).
Take ATACAND exactly as prescribed, typically once daily with or without food.,Do not use if pregnant or planning pregnancy; consult doctor immediately if pregnancy occurs.,May cause dizziness or lightheadedness, especially during initial therapy; avoid driving until effects are known.,Avoid potassium supplements or salt substitutes containing potassium unless directed by healthcare provider.,Report signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to physician immediately.,Maintain adequate hydration and avoid dehydration (excessive sweating, vomiting, diarrhea).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS vs ATACAND, answered by our medical review team.
MICARDIS is a Angiotensin II Receptor Blocker that works by Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.. ATACAND is a Angiotensin II Receptor Blocker that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS and ATACAND depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS is: 40-80 mg orally once daily.. The standard adult dose of ATACAND is: Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS and ATACAND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used during the second and third trimesters. First trimester expos. ATACAND is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, sk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.